India is one of the world’s largest producers of generic medicines, supplying over 20% of the global demand by volume. With this scale comes the critical responsibility of ensuring drug quality and safety. The Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, operates a comprehensive quality monitoring system that protects both domestic patients and international buyers.<\/p>\n\n\n\n
In this guide, we explain how CDSCO monitors drug quality through NSQ (Not of Standard Quality) alerts, factory inspections, laboratory testing, and the new 2026 risk-based classification system \u2014 and what these processes mean for you as an international buyer of Indian generics.<\/p>\n\n\n\n
The CDSCO is the national regulatory authority for pharmaceuticals and medical devices in India, operating under the Ministry of Health and Family Welfare. Its primary responsibilities include:<\/p>\n\n\n\n
The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 form the legal backbone of CDSCO’s authority. In 2025\u20132026, the regulator has undergone significant modernization to strengthen its oversight capabilities (as reported by The Pharma Letter<\/em>, February 2026).<\/p>\n\n\n\n One of CDSCO’s most transparent quality control mechanisms is the monthly NSQ alert system. Every month, the regulator publishes a list of drug samples that have failed quality testing.<\/p>\n\n\n\n What this means:<\/strong> These numbers represent a fraction of the total drug samples tested each month. The vast majority of Indian generic medicines meet quality standards. The NSQ system demonstrates CDSCO’s commitment to transparency \u2014 it publicly names failing manufacturers and removes substandard products from the supply chain.<\/p>\n\n\n\n In March 2026, the Indian government introduced a landmark 3-tier risk-based classification system<\/strong> for drug manufacturing facilities, as detailed by India Briefing<\/em> (March 2026). This system categorizes manufacturers based on their compliance history and risk profile:<\/p>\n\n\n\n This classification is a significant step toward aligning India’s regulatory framework with global best practices, similar to the USFDA’s risk-based inspection scheduling model. It means that international buyers can increasingly rely on a manufacturer’s tier status as a quick proxy for quality reliability.<\/p>\n\n\n\n CDSCO, in coordination with State Drug Control Authorities, conducts routine and for-cause inspections of drug manufacturing facilities across India. Key aspects include:<\/p>\n\n\n\n India’s Schedule M was revised in 2024 to align more closely with WHO-GMP standards, requiring manufacturers to implement quality management systems, validated processes, and comprehensive documentation \u2014 bringing Indian generics closer to international quality benchmarks.<\/p>\n\n\n\n As an international buyer of Indian generic medicines, CDSCO’s quality monitoring system is your ally \u2014 not an obstacle. Here is what you should check when evaluating a supplier:<\/p>\n\n\n\n For a list of verified and reliable pharmaceutical distributors who source only from CDSCO-compliant manufacturers, refer to the IMSDA’s verified member directory<\/a>.<\/p>\n\n\n\n It is important to understand the different classifications CDSCO uses when flagging drugs:<\/p>\n\n\n\n The distinction matters: NSQ findings indicate a quality control failure at the manufacturing level (often correctable), while spurious findings indicate criminal counterfeiting.<\/p>\n\n\n\n In 2026, CDSCO is implementing several reforms aimed at elevating its standing as a Stringent Regulatory Authority (SRA) \u2014 a status that would allow Indian drug approvals to be recognized by major global regulators like the USFDA and EMA:<\/p>\n\n\n\n These reforms signal a clear trajectory: Indian generic medicines are becoming safer, better regulated, and more trusted on the global stage.<\/p>\n\n\n\n Use this checklist when evaluating an Indian generic medicine supplier:<\/p>\n\n\n\n For more information about sourcing quality Indian generic medicines, contact IMSDA at contact@indiamedicine.org.<\/p>\n","protected":false},"excerpt":{"rendered":" 🔬 How CDSCO Monitors Drug Quality in India: Understanding NSQ Alerts, Factory Inspections & What International Buyers Should Know India is one of the world’s largest producers of generic medicines, supplying over 20% of the global demand by volume. With this scale comes the critical responsibility of ensuring drug quality and safety. The Central Drugs […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,41,29],"class_list":["post-3573","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-fda","tag-india-pharmacy","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3573"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3573\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\n🛡️ The NSQ (Not of Standard Quality) Alert System<\/h2>\n\n\n\n
Recent NSQ Data (2025\u20132026)<\/h3>\n\n\n\n
\n
\n\n\n\n🏭 India’s 2026 3-Tier Risk-Based Manufacturing Classification<\/h2>\n\n\n\n
\n
\n\n\n\n🔎 CDSCO’s Factory Inspection and GMP Audit Process<\/h2>\n\n\n\n
\n
\n\n\n\n🌍 What International Buyers Should Look For<\/h2>\n\n\n\n
\n
\n\n\n\n⚠️ Distinguishing “NSQ” from “Spurious” and “Adulterated”<\/h2>\n\n\n\n
\n
\n\n\n\n🔮 The Future: CDSCO’s Path to Global Credibility<\/h2>\n\n\n\n
\n
\n\n\n\n✅ Quick Checklist for International Buyers<\/h2>\n\n\n\n
\n
\n\n\n\n